the SmallCapReview mailing list.
Myriad Genetics: A
personalized medicine company, that focuses on the
development and marketing of predictive, personalized, and
prognostic medicine tests worldwide.
MYGN has a collaboration with AstraZeneca for the
development of an indication for BRACAnalysis CDx. More.
Aurinia Pharmaceuticals: A
late-stage biopharmaceutical company providing novel products specifically
engineered to treat a limited, targeted patient population suffering from
serious disease states for which there is a high unmet medical need.
Intercept Pharmaceuticals: A biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases utilizing its expertise in bile acid chemistry. OCA has received orphan drug
designation in both the United States and Europe for the treatment of PBC.
Where Small Cap Stocks Thrive Since
Small Caps Breaking Out To New Highs
Small Cap Pause That Refreshes...
Completes Licensing Deal With Merck Animal Health...(AUPH)
Small Cap Investing Handbook...
Defense Stocks Easily Outperform Broader Market...
Small Caps For The Long Term...
Of U.S. Small Cap Stocks 2017...
Small Cap Stocks With Wide Moats...
Stocks To Watch...
has the potential to become a best in class medication and the first
approved treatment for LN in the U.S. and Europe."
on AUPH here...
has the deepest diagnostic pipeline across the disease spectrum."
on MYGN here...
Biopharmaceutical Company Focused On The Development And Commercialization Of
Novel Therapeutics To Treat Chronic Liver Diseases."
More On ICPT here...
Subscribers to our Free
newsletter will receive stock reports and news alerts for small-cap stocks
via email. You can sign-up
"A Primer In
is a leading destination for small-cap picks and news. The Purpose of
is to profile and bring awareness to companies with a market cap of
less than $1 billion, these small-cap stocks will primarily trade on the Nasdaq Small-Cap market. We also issue daily small cap
stocks to watch via various newswires. We will strive to bring you the
undiscovered, the undervalued, and the oversold.
does not give "buy" recommendations, price targets nor
suggest entry and exit points.
"A Look at Small Cap Stocks that may no longer be Small Caps"